Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nanotechnological Advances in the Treatment of Epilepsy

Author(s): Ola Asem Mahmoud Abdou Ali, Mohd. Farooq Shaikh, M Saquib Hasnain, Farheen Sami, Abdullah Khan and Mohammed Tahir Ansari*

Volume 21, Issue 10, 2022

Published on: 07 February, 2022

Page: [994 - 1003] Pages: 10

DOI: 10.2174/1871527321666211221162104

Price: $65

Abstract

Epilepsy is known as one of the major challenges for medical science. The sudden appearance of a seizure has been a significant health emergency as it may lead to further complications. Although key advancements have been achieved in terms of pharmacological approaches for epilepsy, many issues remain uncertain. Lipid carriers have been at the forefront, especially in neurodegenerative diseases, such as epilepsy, Alzheimer’s, dementia, etc. The blood-brain barrier still appears to be a major impediment in the successful treatment of epileptic seizures. This is mainly due to the limited bioavailability of most anti-convulsant drugs. The present review encompasses the issues underlying the current approach for epilepsy drug treatment and highlights the newer, novel, and more precise drug delivery system to manage seizures. The advantage of using a lipidbased delivery system is its superior absorption in the brain cells. Ample evidence shows that reducing the particle size also infuses the drug easily through the blood-brain barrier. The application of liposomes, polymeric nanoparticles, metallic nanoparticles, and solid lipid nanoparticles for the treatment and management of epilepsy has been highlighted in the present review. This review provides an overview of the current status of the treatment and recent advances in the treatment of epilepsy.

Keywords: Epilepsy, liposomes, nanoparticles, blood brain barrier, metallic, resistance.

« Previous Next »
[1]
Badgujar VB, Ansari MT, Abdullah MS, Badgujar SV. Homoharringtonne: A nascent phytochemical for cancer treatment (A review). World J Pharm Pharm Sci 2015; 5(1): 421-32.
[2]
Das SS, Alkahtani S, Bharadwaj P, et al. Molecular insights and novel approaches for targeting tumor metastasis. Int J Pharm 2020; 585: 119556.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119556] [PMID: 32574684]
[3]
Siuly S, Zhang Y. Medical big data: Neurological diseases diagnosis through medical data analysis. Data Sci Eng 2016; 1(2): 54-64.
[http://dx.doi.org/10.1007/s41019-016-0011-3]
[4]
Logroscino G, Tortelli R. Epidemiology of neurodegenerative diseases. Imaging in Neurodegenerative Disorders. United Kingdom: Oxford University Press 2015.
[http://dx.doi.org/10.1093/med/9780199671618.003.0001]
[5]
Alarcón G. What is epilespy? Introduction to Epilepsy. United Kingdom: Cambridge University Press 2012; pp. 6-7.
[http://dx.doi.org/10.1017/CBO9781139103992.004]
[6]
Beghi E. The epidemiology of epilepsy. Neuroepidemiology 2020; 54(2): 185-91.
[http://dx.doi.org/10.1159/000503831] [PMID: 31852003]
[7]
Epilepsy. World health organisation (WHO). 2019.
[8]
Morrison-Valfre M. Cognitive impairement, alzheimer's disease and dementia. Foundations of Mental Health Care. Maryland Heights: Mosby 2020.
[9]
Qiu C, Kivipelto M, von Strauss E. Epidemiology of alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009; 11(2): 111-28.
[http://dx.doi.org/10.31887/DCNS.2009.11.2/cqiu] [PMID: 19585947]
[10]
Dementia World Health Organisation (WHO) 2020.
[11]
de La Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol 2012; 2012: 367516.
[http://dx.doi.org/10.1155/2012/367516]
[12]
Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet 2014; 383(9913): 245-54.
[http://dx.doi.org/10.1016/S0140-6736(13)61953-4] [PMID: 24449944]
[13]
Abou-Khalil B, Schmidt D. Antiepileptic drugs: Advantages and disadvantages. Handb Clin Neurol 2012; 108: 723-39.
[http://dx.doi.org/10.1016/B978-0-444-52899-5.00024-1] [PMID: 22939062]
[14]
Franco V, French JA, Perucca E. Challenges in the clinical development of new antiepileptic drugs. Pharmacol Res 2016; 103: 95-104.
[http://dx.doi.org/10.1016/j.phrs.2015.11.007] [PMID: 26611249]
[15]
Schmidt D. Drug treatment of epilepsy: Options and limitations. Epilepsy Behav 2009; 15(1): 56-65.
[http://dx.doi.org/10.1016/j.yebeh.2009.02.030]
[16]
Deckers CL, Genton P, Sills GJ, Schmidt D. Current limitations of antiepileptic drug therapy: A conference review. Epilepsy Res 2003; 53(1-2): 1-17.
[http://dx.doi.org/10.1016/S0920-1211(02)00257-7] [PMID: 12576163]
[17]
Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial. Lancet 2007; 369(9566): 1000-15.
[http://dx.doi.org/10.1016/S0140-6736(07)60460-7] [PMID: 17382827]
[18]
Chaves J, Sander JW. Seizure aggravation in idiopathic generalized epilepsies. Epilepsia 2005; 46(s9)(Suppl. 9): 133-9.
[http://dx.doi.org/10.1111/j.1528-1167.2005.00325.x] [PMID: 16302887]
[19]
Gelisse P, Genton P, Kuate C, Pesenti A, Baldy-Moulinier M, Crespel A. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45(10): 1282-6.
[http://dx.doi.org/10.1111/j.0013-9580.2004.19704.x] [PMID: 15461683]
[20]
French JA. Seizure exacerbation by antiepileptic drugs. Epilepsy Curr 2005; 5(5): 192-3.
[http://dx.doi.org/10.1111/j.1535-7511.2005.00061.x] [PMID: 16175222]
[21]
So EL, Ruggles KH, Cascino GD, Ahmann PA, Weatherford KW. Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide. Ann Neurol 1994; 35(6): 743-6.
[http://dx.doi.org/10.1002/ana.410350616] [PMID: 8210232]
[22]
Candy N, Tsimiklis C, Poonnoose S, Trivedi R. The use of antiepileptic medication in early post traumatic seizure prophylaxis at a single institution. J Clin Neurosci 2019; 69: 198-205.
[http://dx.doi.org/10.1016/j.jocn.2019.07.066]
[23]
Schmidt D, Schachter SC, Eds. Case 96 - Why Do Some Patients Seem to Develop Tolerance to AEDs? Development of Antiepileptic Drug Tolerance in a Patient with Temporal Lobe Epilepsy. Puzzling Cases of Epilepsy. 2nd ed. San Diego: Academic Press 2008; pp. 420-32.
[http://dx.doi.org/10.1016/B978-0-12-374005-2.00096-X]
[24]
Avanzini G. Is tolerance to antiepileptic drugs clinically relevant? Epilepsia 2006; 47(8): 1285-7.
[http://dx.doi.org/10.1111/j.1528-1167.2006.00616.x] [PMID: 16922871]
[25]
Löscher W, Friedman A. Structural, molecular, and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: A cause, consequence, or both? Int J Mol Sci 2020; 21(2): 591.
[http://dx.doi.org/10.3390/ijms21020591] [PMID: 31963328]
[26]
Iorio AL, Ros Md, Fantappiè O, et al. Blood-brain barrier and breast cancer resistance protein: A limit to the therapy of CNS tumors and neurodegenerative diseases. Anticancer Agents Med Chem 2016; 16(7): 810-5.
[http://dx.doi.org/10.2174/1871520616666151120121928] [PMID: 26584727]
[27]
Rempe RG, Hartz AMS, Soldner ELB, et al. Matrix metalloproteinase-mediated blood-brain barrier dysfunction in epilepsy. J Neurosci 2018; 38(18): 4301-15.
[http://dx.doi.org/10.1523/JNEUROSCI.2751-17.2018] [PMID: 29632167]
[28]
Han H, Mann A, Ekstein D, Eyal S. Breaking bad: The structure and function of the blood-brain barrier in epilepsy. AAPS J 2017; 19(4): 973-88.
[http://dx.doi.org/10.1208/s12248-017-0096-2] [PMID: 28550637]
[29]
Banks WA. From blood-brain barrier to blood-brain interface: New opportunities for CNS drug delivery. Nat Rev Drug Discov 2016; 15(4): 275-92.
[http://dx.doi.org/10.1038/nrd.2015.21] [PMID: 26794270]
[30]
Dalic L, Cook MJ. Managing drug-resistant epilepsy: Challenges and solutions. Neuropsychiatr Dis Treat 2016; 12: 2605-16.
[http://dx.doi.org/10.2147/NDT.S84852] [PMID: 27789949]
[31]
Santulli L, Coppola A, Balestrini S, Striano S. The challenges of treating epilepsy with 25 antiepileptic drugs. Pharmacol Res 2016; 107: 211-9.
[http://dx.doi.org/10.1016/j.phrs.2016.03.016] [PMID: 26995307]
[32]
Zamay TN, Zamay GS, Shnayder NA, et al. Nucleic acid aptamers for molecular therapy of epilepsy and blood-brain barrier damages. Mol Ther Nucleic Acids 2020; 19: 157-67.
[http://dx.doi.org/10.1016/j.omtn.2019.10.042] [PMID: 31837605]
[33]
Holmes GL, Noebels JL. The epilepsy spectrum: Targeting future research challenges. Cold Spring Harb Perspect Med 2016; 6(7): a028043.
[http://dx.doi.org/10.1101/cshperspect.a028043] [PMID: 27371672]
[34]
Ansari MT, Ramlan TA, Jamaluddin NNB, et al. Lipid based nano carriers for cancer and tumor treatment. Curr Pharm Des 2020; 26(34): 4272-6.
[http://dx.doi.org/10.2174/1381612826666200720235752] [PMID: 32693760]
[35]
Grabrucker AM, Ruozi B, Belletti D, et al. Nanoparticle transport across the blood brain barrier. Tissue Barriers 2016; 4(1): e1153568.
[http://dx.doi.org/10.1080/21688370.2016.1153568] [PMID: 27141426]
[36]
Zeeshan M, Mukhtar M, Ul Ain Q, Khan S, Ali H. Nanopharmaceuticals: A Boon to the Brain-Targeted Drug Delivery. Pharmaceutical Formulation Design - Recent Practices: IntechOpen 2020.
[http://dx.doi.org/10.5772/intechopen.83040]
[37]
Liu S, Yang S, Ho PC. Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain. Asian J Pharm Sci 2018; 13(1): 72-81.
[http://dx.doi.org/10.1016/j.ajps.2017.09.001] [PMID: 32104380]
[38]
Pattnaik A, Ashok Kumar P, Prasanta Kumar B, Biswaranjan R. Nanoliposomes: Tools for target drug delivery system. Int J Pharm Health Care Res 2018; 6(4): 117-27.
[39]
Costa C, Moreira JN, Amaral MH, Sousa Lobo JM, Silva AC. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Control Release 2019; 295: 187-200.
[http://dx.doi.org/10.1016/j.jconrel.2018.12.049] [PMID: 30610952]
[40]
Hasan M, Elkhoury K, Kahn CJF, Arab-Tehrany E, Linder M. Preparation, characterization, and release kinetics of chitosan-coated nanoliposomes encapsulating curcumin in simulated environments. Molecules 2019; 24(10): 2023.
[http://dx.doi.org/10.3390/molecules24102023] [PMID: 31137865]
[41]
Montesinos RN. Liposomes. Liposomal drug delivery to the central nervous system. London: InTech 2017.
[http://dx.doi.org/10.5772/intechopen.70055]
[42]
Praveen A, Aqil M, Imam SS, Ahad A, Moolakkadath T, Ahmad FJ. Lamotrigine encapsulated intra-nasal nanoliposome formulation for epilepsy treatment: Formulation design, characterization and nasal toxicity study. Colloids Surf B Biointerfaces 2019; 174: 553-62.
[http://dx.doi.org/10.1016/j.colsurfb.2018.11.025] [PMID: 30502666]
[43]
Naqvi S, Panghal A, Flora SJS. Nanotechnology: A promising approach for delivery of neuroprotective drugs. Front Neurosci 2020; 14: 494.
[http://dx.doi.org/10.3389/fnins.2020.00494] [PMID: 32581676]
[44]
Jin G-Z, Chakraborty A, Lee J-H, Knowles JC, Kim H-W. Targeting with nanoparticles for the therapeutic treatment of brain diseases. J Tissue Eng 2020; 11: 2041731419897460.
[http://dx.doi.org/10.1177/2041731419897460] [PMID: 32180936]
[45]
Moreno LC, Cavalcanti IM, Satyal P, Santos-Magalhães NS, Rolim HM, Freitas RM. Acute toxicity and anticonvulsant activity of liposomes containing nimodipine on pilocarpine-induced seizures in mice. Neurosci Lett 2015; 585: 38-42.
[http://dx.doi.org/10.1016/j.neulet.2014.11.025] [PMID: 25445375]
[46]
Jabir NR, Tabrez S, Firoz CK, et al. A Synopsis of nano-technological approaches toward anti-epilepsy therapy: Present and future research implications. Curr Drug Metab 2015; 16(5): 336-45.
[http://dx.doi.org/10.2174/1389200215666141125142605] [PMID: 25429676]
[47]
Mori N, Kurokouchi A, Osonoe K, et al. Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats. Brain Res 1995; 703(1-2): 184-90.
[http://dx.doi.org/10.1016/0006-8993(95)01095-5] [PMID: 8719631]
[48]
Agarwal NB, Jain S, Nagpal D, Agarwal NK, Mediratta PK, Sharma KK. Liposomal formulation of curcumin attenuates seizures in different experimental models of epilepsy in mice. Fundam Clin Pharmacol 2013; 27(2): 169-72.
[http://dx.doi.org/10.1111/j.1472-8206.2011.01002.x] [PMID: 22044441]
[49]
Dhir A. Curcumin in epilepsy disorders. Phytother Res 2018; 32(10): 1865-75.
[http://dx.doi.org/10.1002/ptr.6125] [PMID: 29917276]
[50]
Kohane DS, Holmes GL, Chau Y, Zurakowski D, Langer R, Cha BH. Effectiveness of muscimol-containing microparticles against pilocarpine-induced focal seizures. Epilepsia 2002; 43(12): 1462-8.
[http://dx.doi.org/10.1046/j.1528-1157.2002.11202.x] [PMID: 12460246]
[51]
Zasada K, Łukasiewicz-Atanasov M, Kłysik K, et al. ‘One-component’ ultrathin multilayer films based on poly(vinyl alcohol) as stabilizing coating for phenytoin-loaded liposomes. Colloids Surf B Biointerfaces 2015; 135: 133-42.
[http://dx.doi.org/10.1016/j.colsurfb.2015.07.033] [PMID: 26253533]
[52]
Nagpal D, Agarwal N, Katare D. Evaluation of liposomal gossypin in animal models of epilepsy. Int J Pharm Pharm Sci 2016; 8: 247-51.
[53]
Musumeci T, Serapide MF, Pellitteri R, et al. Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents. Eur J Pharm Biopharm 2018; 133: 309-20.
[http://dx.doi.org/10.1016/j.ejpb.2018.11.002] [PMID: 30399400]
[54]
Majeed S, Danish M, Ibrahim MNM, et al. Bacteria mediated synthesis of iron oxide nanoparticles and their antibacterial, antioxidant, cytocompatibility properties. J Cluster Sci 2020; 1-12.
[55]
Majeed S, Danish M, Ismail MHB, Ansari MT, Ibrahim MNM. Anticancer and apoptotic activity of biologically synthesized zinc oxide nanoparticles against human colon cancer HCT-116 cell line-in vitro study. Sustain Chem Pharm 2019; 14: 100179.
[http://dx.doi.org/10.1016/j.scp.2019.100179]
[56]
Ansari MT, Sami F, Khairudiin FA, Atan MZ. Applications of zinc nanoparticles in medical and healthcare fields. Curr Nanomed 2018; 8(3): 225-33.
[57]
Majeed S. bin Abdullah MS, Nanda A, Ansari MT. in vitro study of the antibacterial and anticancer activities of silver nanoparticles synthesized from Penicillium brevicompactum (MTCC-1999). J Taibah Univ Sci 2016; 10(4): 614-20.
[http://dx.doi.org/10.1016/j.jtusci.2016.02.010]
[58]
Majeed S, Abdullah MS, Dash GK, Ansari MT, Nanda A. Biochemical synthesis of silver nanoprticles using filamentous fungi Penicillium decumbens (MTCC-2494) and its efficacy against A-549 lung cancer cell line. Chin J Nat Med 2016; 14(8): 615-20.
[http://dx.doi.org/10.1016/S1875-5364(16)30072-3] [PMID: 27608951]
[59]
Ahmad SA, Das SS, Khatoon A, et al. Bactericidal activity of silver nanoparticles: A mechanistic review. Mater Sci Energy Technol 2020; 3: 756-69.
[60]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology 2018; 16(1): 71.
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[61]
Aghaie T, Jazayeri MH, Manian M, et al. Gold nanoparticle and polyethylene glycol in neural regeneration in the treatment of neurodegenerative diseases. J Cell Biochem 2019; 120(3): 2749-55.
[http://dx.doi.org/10.1002/jcb.27415] [PMID: 30485477]
[62]
Ugur Yilmaz C, Emik S, Orhan N, et al. Targeted delivery of lacosamide-conjugated gold nanoparticles into the brain in temporal lobe epilepsy in rats. Life Sci 2020; 257: 118081.
[http://dx.doi.org/10.1016/j.lfs.2020.118081] [PMID: 32663576]
[63]
Zhu D, Zhang WG, Nie XD, Ding SW, Zhang DT, Yang L. Rational design of ultra-small photoluminescent copper nano-dots loaded PLGA micro-vessels for targeted co-delivery of natural piperine molecules for the treatment for epilepsy. J Photochem Photobiol B 2020; 205: 111805.
[http://dx.doi.org/10.1016/j.jphotobiol.2020.111805] [PMID: 32092661]
[64]
Ross AM, Mc Nulty D, O’Dwyer C, Grabrucker AM, Cronin P, Mulvihill JJE. Standardization of research methods employed in assessing the interaction between metallic-based nanoparticles and the blood-brain barrier: Present and future perspectives. J Control Release 2019; 296: 202-24.
[http://dx.doi.org/10.1016/j.jconrel.2019.01.022] [PMID: 30664977]
[65]
Rosillo-de la Torre A, Zurita-Olvera L, Orozco-Suárez S, et al. Phenytoin carried by silica core iron oxide nanoparticles reduces the expression of pharmacoresistant seizures in rats. Nanomedicine (Lond) 2015; 10(24): 3563-77.
[http://dx.doi.org/10.2217/nnm.15.173] [PMID: 26649451]
[66]
Wang Y, Wang Y, Sun R, et al. The treatment value of IL-1β monoclonal antibody under the targeting location of alpha-methyl-l-tryptophan and superparamagnetic iron oxide nanoparticles in an acute temporal lobe epilepsy model. J Transl Med 2018; 16(1): 337.
[http://dx.doi.org/10.1186/s12967-018-1712-3]
[67]
Abbas H, Refai H, El Sayed N. Superparamagnetic iron oxide-loaded lipid nanocarriers incorporated in thermosensitive in situ gel for magnetic brain targeting of clonazepam. J Pharm Sci 2018; 107(8): 2119-27.
[http://dx.doi.org/10.1016/j.xphs.2018.04.007] [PMID: 29665379]
[68]
Ansari MT, Risheshwar P, Ali S. Effects of polymers on complexation efficiency of aceclofenac-beta cyclodextrin inclusion complex. Int J Pharm Bio Sci 2017; 8(4): 21-9.
[http://dx.doi.org/10.22376/ijpbs.2017.8.4.p21-29]
[69]
Ansari MT, Risheshwar P, Ali S. Effect of hydroxy acids and organic bases on complexation efficiency of Aceclofenac Beta Cyclodextrin inclusion complex. European J Biomed Pharm Sci 2017; 4(5): 586-9.
[70]
Hashemian M, Ghasemi-Kasman M, Ghasemi S, et al. Fabrication and evaluation of novel quercetin-conjugated Fe3O4-β-cyclodextrin nanoparticles for potential use in epilepsy disorder. Int J Nanomedicine 2019; 14: 6481-95.
[http://dx.doi.org/10.2147/IJN.S218317] [PMID: 31496698]
[71]
Yurtdaş Kırımlıoğlu G, Menceloğlu Y, Erol K, Yazan Y. In vitro/in vivo evaluation of gamma-aminobutyric acid-loadedN,N-dimethylacrylamide-based pegylated polymeric nanoparticles for brain delivery to treat epilepsy. J Microencapsul 2016; 33(7): 625-35.
[http://dx.doi.org/10.1080/02652048.2016.1234515] [PMID: 27606701]
[72]
Ozer I, Chilkoti A. Site-Specific and Stoichiometric Stealth Polymer Conjugates of Therapeutic Peptides and Proteins. Bioconjug Chem 2017; 28(3): 713-23.
[http://dx.doi.org/10.1021/acs.bioconjchem.6b00652] [PMID: 27998056]
[73]
Ulbrich K, Holá K, Šubr V, Bakandritsos A, Tuček J, Zbořil R. Targeted drug delivery with polymers and magnetic nanoparticles: Covalent and noncovalent approaches, release control, and clinical studies. Chem Rev 2016; 116(9): 5338-431.
[http://dx.doi.org/10.1021/acs.chemrev.5b00589] [PMID: 27109701]
[74]
Sant S, Swati S, Awadhesh K, Sajid M, Pattnaik G, Tahir M, et al. Hydrophilic polymers as release modifiers for primaquine phosphate: Effect of polymeric dispersion. ARS Pharmaceutica 2011; 52(9): 19-25.
[75]
Nayak AK, Ansari MT, Sami F, Singh HKB, Hasnain MS. Alginates as drug delivery excipients. Alginates in Drug Delivery. Cambridge: Academic Press 2020; pp. 19-39.
[http://dx.doi.org/10.1016/B978-0-12-817640-5.00002-9]
[76]
Das S, Pattanayak D, Nayak AK, Yi DK, Nanda SS, Ansari MT, et al. Alginate–montmorillonite composite systems as sustained drug delivery carriers. Alginates in Drug Delivery. Cambridge: Academic Press 2020; pp. 187-201.
[77]
Nayak AK, Mazumder S, Ara TJ, Ansari MT, Hasnain MS. Calcium fluoride-based dental nanocomposites. Applications of Nanocomposite Materials in Dentistry. Sawston, UK: Woodhead Publishing 2019; pp. 27-45.
[http://dx.doi.org/10.1016/B978-0-12-813742-0.00002-X]
[78]
Nayak AK, Ansari MT, Sami F, Bera H, Hasnain MS. Cashew gum in drug delivery applications. Natural Polysaccharides in Drug Delivery and Biomedical Applications. Cambridge: Academic Press 2019; pp. 263-83.
[http://dx.doi.org/10.1016/B978-0-12-817055-7.00011-X]
[79]
Nayak AK, Ansari MT, Pal D, Hasnain MS. Hyaluronic acid (hyaluronan): Pharmaceutical Application Natural Polymers for Pharmaceutical Applications: Animal Derived Polymers 3. Apple Academic Press, Elsevier Publications 2019; pp. 1-32.
[80]
Zhao Y, Zheng C, Liu Y. Polymeric Nanomedicine. Nanomedicine in Brain Diseases. Singapore: Springer 2019; pp. 233-67.
[http://dx.doi.org/10.1007/978-981-13-8731-9_9]
[81]
Cano A, Ettcheto M, Espina M, et al. Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. Nanomedicine 2018; 14(4): 1073-85.
[http://dx.doi.org/10.1016/j.nano.2018.01.019] [PMID: 29454994]
[82]
Liu D, Yang F, Xiong F, Gu N. The smart drug delivery system and its clinical potential. Theranostics 2016; 6(9): 1306-23.
[http://dx.doi.org/10.7150/thno.14858] [PMID: 27375781]
[83]
Duan Y, Dhar A, Patel C, et al. A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC Adv 2020; 10(45): 26777-91.
[http://dx.doi.org/10.1039/D0RA03491F]
[84]
Jahangir MA, Gilani SJ, Muheem A, et al. Quantum dots: Next generation of smart nano-systems. Pharm Nanotechnol 2019; 7(3): 234-45.
[http://dx.doi.org/10.2174/2211738507666190429113906] [PMID: 31486752]
[85]
Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. BioMed Res Int 2014; 2014: 869269.
[http://dx.doi.org/10.1155/2014/869269] [PMID: 25136634]
[86]
Huang R, Zhu Y, Lin L, Song S, Cheng L, Zhu R. Solid lipid nanoparticles enhanced the neuroprotective role of curcumin against epilepsy through activation of Bcl-2 family and P38 MAPK pathways. ACS Chem Neurosci 2020; 11(13): 1985-95.
[http://dx.doi.org/10.1021/acschemneuro.0c00242] [PMID: 32464055]
[87]
Qushawy M, Prabahar K, Abd-Alhaseeb M, Swidan S, Nasr A. Preparation and Evaluation of Carbamazepine Solid Lipid Nanoparticle for Alleviating Seizure Activity in Pentylenetetrazole-Kindled Mice. Molecules 2019; 24(21): 3971.
[http://dx.doi.org/10.3390/molecules24213971] [PMID: 31684021]
[88]
Ashhar MU, Ahmad MZ, Jain V, Agarwal NB, Ahmad FJ, Jain GK. Intranasal pitavastatin attenuates seizures in different experimental models of epilepsy in mice. Epilepsy Behav 2017; 75: 56-9.
[http://dx.doi.org/10.1016/j.yebeh.2017.07.004]
[89]
Neves AR, Queiroz JF, Reis S. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnology 2016; 14(1): 27.
[http://dx.doi.org/10.1186/s12951-016-0177-x] [PMID: 27061902]
[90]
Alam T, Pandit J, Vohora D, Aqil M, Ali A, Sultana Y. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: In vitro characterization and in vivo efficacy in epilepsy. Expert Opin Drug Deliv 2015; 12(2): 181-94.
[http://dx.doi.org/10.1517/17425247.2014.945416] [PMID: 25164097]
[91]
Criscione Jason M, Werth Nicholas B, Langer Robert S, et al. Methods for treating epilepsy or seizure disorders. US patent 2016/0136095 A1, 2015.
[92]
Raman S, Kannan R, Vimal J. Mono disperse polymer nanoparticles, functionalized nanoparticles and controlled formation method. US patent 2016/0243051 A1, 2014.
[93]
Nagare S, Senna M. Drug Nano-particle, Method And Apparatus For Preparing Pharmaceutical Preparation Using The Particle. US patent US 2006/0251584 A1, 2004.
[94]
Chow AHL, Chow SF, Zhang XR, Wan KY, Cheng KK, Baum LW. Engineering of polymer-stabilized nanoparticles for drugs with log p values below 6 by controlled antisolvent precipitation. US patent 10076496 B2, 2012.
[95]
Javed M, Pottoo F, Alam M. Metallic nanoparticle alone and/or in combination as novel agent for the treatment of uncontrolled electric conductance related disorders and/or seizure, epilepsy & convulsions. WO Patent 2017060916A1, 2016.
[96]
Meyre M-E, Levy L, Pottier A. Nanoparticles for use for treating a neuronal disorder. AU patent 2018391789 A1, 2018.

Rights & Permissions Print Cite
Article Metrics
81
2
© 2024 Bentham Science Publishers | Privacy Policy